Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.42 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492188 | 0.92 | CHRNB2 (0.44) | HRH1HTR2ACASRCA12CA1 | |
| SCHEMBL6981260 | 0.89 | LMNA (0.48) | HRH1HTR2ALMNAALDH1A1ALOX15 | |
| SCHEMBL13527883 | 0.87 | KDM4E (0.52) | HRH1HTR2ALMNAALDH1A1ALOX15 | |
| SCHEMBL10472662 | 0.85 | RIPK1 (0.46) | LMNAALDH1A1ALOX15KDM4EUSP2 | |
| SCHEMBL11044391 | 0.84 | MMP13 (0.39) | HRH1HTR2ALMNAALDH1A1ALOX15 | |
| SCHEMBL974205 | 0.84 | RIPK1 (0.47) | LMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL974206 | 0.84 | RIPK1 (0.47) | LMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5303572 | 0.84 | RIPK1 (0.47) | LMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12283380 | 0.82 | CCR5 (0.45) | LMNAALDH1A1ALOX15KDM4EUSP2 | |
| SCHEMBL12406856 | 0.82 | CYP1A2 (0.38) | LMNAALDH1A1ALOX15KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198902-B2 | 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9198902-B2 | 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9198902-B2 | 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-8927579-B2 | Male contraceptive | Amobi, Nnaemkea Ikechukwu (GB) | 2015-01-06 | — | — | US | disclosed |
| US-8927579-B2 | Male contraceptive | Amobi, Nnaemkea Ikechukwu (GB) | 2015-01-06 | — | — | US | disclosed |
| US-8778968-B2 | — | — | 2014-07-15 | — | — | US | disclosed |
| US-8778968-B2 | — | — | 2014-07-15 | — | — | US | disclosed |
| EP-2703398-A1 | 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703398-A1 | 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045896-A1 | 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2014-02-13 | — | — | US | disclosed |
| EP-0988289-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0914319-A1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998055454-A2 | BENZOFURANS AND BENZOTHOPHENES AS SUPPRESSORS OF NEURODEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
| US-5773469-A | Diaryl antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997044329-A9 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | — | 1998-03-12 | — | — | WO | disclosed |
| WO-1997048674-A1 | DIARYL ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997044329-A1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 1997-11-27 | — | — | WO | disclosed |
| US-3935268-A | CEREBRAL VASCULAR DISEASES | DAINIPPON PHARMACEUTICAL CO., LTD. (JA) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045896-A1 | 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof | PKD1, REN, GLS | HRH1 490/4885HTR2A 2720/4885LMNA 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.